UNICHEMLAB

Unichem Laboratories Share Price

₹686.45 +9.35 (1.38%)

14 Jan, 2025 16:14

SIP TrendupStart SIP in UNICHEMLAB

Start SIP

Performance

  • Low
  • ₹672
  • High
  • ₹689
  • 52 Week Low
  • ₹440
  • 52 Week High
  • ₹938
  • Open Price₹672
  • Previous Close₹677
  • Volume7,368

Investment Returns

  • Over 1 Month -11.98%
  • Over 3 Month -3.41%
  • Over 6 Month + 29.01%
  • Over 1 Year + 49.33%
SIP Lightning

Smart Investing Starts Here Start SIP with Unichem Laboratories for Steady Growth!

Invest Now

Unichem Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -867.3
  • PEG Ratio
  • -9.1
  • Market Cap Cr
  • 4,833
  • P/B Ratio
  • 2
  • Average True Range
  • 32.27
  • EPS
  • 7.11
  • Dividend Yield
  • 0
  • MACD Signal
  • -23.14
  • RSI
  • 33.66
  • MFI
  • 43.94

Unichem Laboratories Financials

Unichem Laboratories Technicals

EMA & SMA

Current Price
₹686.45
+ 9.35 (1.38%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹728.07
  • 50 Day
  • ₹750.22
  • 100 Day
  • ₹722.82
  • 200 Day
  • ₹656.29

Resistance and Support

681.03 Pivot Speed
  • R3 715.07
  • R2 705.03
  • R1 691.07
  • S1 667.07
  • S2 657.03
  • S3 643.07

What's your outlook on Unichem Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Unichem Laboratories Ltd. is a leading Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and formulations. It serves domestic and international markets with a focus on quality, research, and innovative healthcare solutions.

Unichem Laboratories has an operating revenue of Rs. 1,774.67 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of -4% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 8% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Unichem Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-09-30 Others
2024-08-08 Quarterly Results
2024-05-22 Audited Results
2024-02-05 Quarterly Results

Unichem Laboratories F&O

Unichem Laboratories Shareholding Pattern

70.22%
10.22%
0.22%
0.94%
0.03%
14.58%
3.79%

About Unichem Laboratories

  • NSE Symbol
  • UNICHEMLAB
  • BSE Symbol
  • 506690
  • Managing Director
  • Mr. Pabitrakumar Bhattacharyya
  • ISIN
  • INE351A01035

Similar Stocks to Unichem Laboratories

Unichem Laboratories FAQs

Unichem Laboratories share price is ₹686 As on 14 January, 2025 | 16:00

The Market Cap of Unichem Laboratories is ₹4833 Cr As on 14 January, 2025 | 16:00

The P/E ratio of Unichem Laboratories is -867.3 As on 14 January, 2025 | 16:00

The PB ratio of Unichem Laboratories is 2 As on 14 January, 2025 | 16:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23